We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

79 hedge funds and large institutions have $225M invested in Karyopharm Therapeutics in 2016 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

310% more call options, than puts

Call options by funds: $762K | Put options by funds: $186K

67% more capital invested

Capital invested by funds: $135M → $225M (+$90.4M)

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

53% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 19

5% more funds holding

Funds holding: 75 → 79 (+4)

Holders
79
Holders Change
+4
Holders Change %
+5.33%
% of All Funds
2.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
29
Reduced
19
Closed
7
Calls
$762K
Puts
$186K
Net Calls
+$576K
Net Calls Change
+$442K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$22.2M
2
Millennium Management
Millennium Management
New York
+$1.26M
3
CS
Candriam SCA
Luxembourg
+$881K
4
BFA
BlackRock Fund Advisors
California
+$621K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$522K

Top Sellers

Rank Fund Capital Flow
1
NLVP
New Leaf Venture Partners
New York
-$1.5M
2
PAI
Palo Alto Investors
California
-$429K
3
TC
TFS Capital
Pennsylvania
-$335K
4
SIP
Stoneridge Investment Partners
Pennsylvania
-$133K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$110K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$52.2M – – –
Wellington Management Group
2
Wellington Management Group
Massachusetts
$41.4M +$22.2M +184,556 +186%
Franklin Resources
3
Franklin Resources
California
$31.9M -$7.33K -61 -0%
PAI
4
Palo Alto Investors
California
$30M -$429K -3,573 -2%
BFA
5
BlackRock Fund Advisors
California
$11.2M +$621K +5,165 +7%
Vanguard Group
6
Vanguard Group
Pennsylvania
$8.58M +$522K +4,344 +8%
Millennium Management
7
Millennium Management
New York
$8.48M +$1.26M +10,517 +22%
BIT
8
BlackRock Institutional Trust
California
$5.25M +$66.2K +551 +2%
TCM
9
Tekla Capital Management
Massachusetts
$4.87M – – –
State Street
10
State Street
Massachusetts
$3.71M +$77.9K +648 +3%
JP Morgan Chase
11
JP Morgan Chase
New York
$3.64M +$96.3K +801 +3%
Northern Trust
12
Northern Trust
Illinois
$2.65M +$119K +989 +6%
CS
13
Candriam SCA
Luxembourg
$2.63M +$881K +7,333 +69%
BBA
14
Baker Bros. Advisors
New York
$2.11M – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.43M +$24.2K +201 +2%
BIM
16
BlackRock Investment Management
Delaware
$992K +$67.3K +560 +9%
Deutsche Bank
17
Deutsche Bank
Germany
$951K +$107K +887 +16%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$854K -$110K -917 -14%
MOACM
19
Mutual of America Capital Management
New York
$851K – – –
RhumbLine Advisers
20
RhumbLine Advisers
Massachusetts
$794K +$137K +1,142 +27%
Charles Schwab
21
Charles Schwab
California
$617K +$23K +191 +5%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$568K +$467K +3,889 New
PCM
23
Piermont Capital Management
Missouri
$507K +$417K +3,472 New
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$485K +$2.4K +20 +0.6%
Goldman Sachs
25
Goldman Sachs
New York
$472K +$58K +483 +18%
1
2 3 4

KPTI Hedge Fund Activity: Q3 2016 in Review

79 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2016, worth a combined $225M — up 67% from $135M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new KPTI positions and 7 closed out — a net gain of 4 holders — while 29 added to existing stakes and 19 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $22.2M. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $1.5M sold.

  • 79 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2016, up from 75 in Q2 2016.
  • Funds reported $225M of Karyopharm Therapeutics stock for Q3 2016, up 67% quarter-over-quarter.
  • 11 funds opened new Karyopharm Therapeutics positions in Q3 2016 and 7 closed out, a net change of +4 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2016 was Wellington Management Group, an estimated $22.2M added.
  • The largest Karyopharm Therapeutics seller in Q3 2016 was New Leaf Venture Partners, an estimated $1.5M sold.

Based on aggregated 13F filings for Q3 2016.